Extremely elevated C-reactive proteinSteven Vanderschueren, Willy Peetermans, Dries Deeren et al.|European Journal of Internal Medicine|2006Cited by 108
Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AMLJordi Esteve Reyner, Pau Montesinos, James M. Foran et al.|Journal of Clinical Oncology|2025Cited by 33
Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilusAmer M. Zeidan, Matteo Della Porta, Lea Sahagun et al.|Blood|2025Cited by 1